Navigation Links
Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
Date:11/10/2009

er or more cost-effective treatment for physicians and patients than other FDA-approved products that currently are or will be on the market; that the Matrix clinical study program or other human clinical trials can be conducted and completed in an efficient and successful manner; that we can develop a DNA-based orthobiologics product portfolio; that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive; that FDA or other regulatory clearances or other certifications, or other commercialization efforts will be successful or will effectively enhance our businesses or their market value; that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population; or that third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2009 Cardium Therapeutics, Inc. All right
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cardium Announces $5.3 Million Registered Direct Offering
2. Cardium Completes $5.3 Million Registered Direct Offering
3. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
4. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
5. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
6. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
7. Cardium Reports on First Quarter 2008 Highlights and Financial Results
8. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
9. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
10. Cardium Launches New AWARE Clinical Study Website
11. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... (PRWEB) June 19, 2013 India’s ... business can potentially be worth up to a ... opportunity, the Indian government is taking serious action ... the process. , This presentation will examine:, ... regulations ,     Immediate and long term impacts ...
(Date:6/19/2013)... Applied Rigaku Technologies, Inc. is pleased to publish ... sulfur in ultra-low sulfur diesel (ULSD) using the new ... . The analysis detailed in Rigaku Application Note 1272 ... International Standard specifies an energy dispersive X-ray fluorescence (EDXRF) ... automotive gasoline. , Regulations around the world have limited ...
(Date:6/19/2013)... A new look at “big glass” and visionary ... highlight technical sessions at SPIE Photomask Technology 2013 ... year, the three-day event is the industry’s largest mask ... 100 technical presentations and numerous networking lunches and receptions. ... and photonics , the meeting will be held at ...
(Date:6/19/2013)... Express Diagnostics Int’l, Inc., manufacturer of ... it has received Class III medical device license approval ... DrugCheck® NxStep Onsite Drug Screen Cup in Canada. ... device in near-patient settings, such as physicians’ offices. , ... Canada Class III approval for 24 different drugs and ...
Breaking Biology Technology:Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 3Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3
... Acquisition Extends Elsevier,s Ability to Gather Global Healthcare News and, ... Increase ... Business Value for Customers, PHILADELPHIA, March 10 ... information, announced,today that it has acquired Windhover Information Inc., a ...
... March 10 Caliper Life,Sciences, Inc. (Nasdaq: ... the,Cowen and Company 28th Annual Health Care Conference ... at 2:30 p.m. EDT. Kevin Hrusovsky, President,and CEO ... the company,s business.,The live webcast can be accessed ...
... used by Avexa to select patients and optimize ... background therapy in phase III program, SOUTH SAN FRANCISCO, ... today that the Company,has signed an agreement with AVEXA Limited (ASX: ... technology in support of,Avexa,s drug discovery and development programs., Avexa ...
Cached Biology Technology:Elsevier Acquires Windhover Information Inc., a Healthcare Business Intelligence Company 2Elsevier Acquires Windhover Information Inc., a Healthcare Business Intelligence Company 3Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts 2Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts 3Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts 4Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts 5
(Date:6/18/2013)... Scientists at the University of Calgary,s Faculty of Medicine ... the body from harmful bacteria. Platelets, a component of ... search for specific bacteria, and upon detection, seal it ... which were published in Nature Immunology this ... of immunity. , "The science community has known that ...
(Date:6/18/2013)... a hacker lab. At Brandeis University, sophisticated computational ... helping scientists understand the complex interplay between genomic ... virus, outer "shell" critical for replication. ... we are finding will help researchers alter virus ... fellow Jason Perlmutter, first author of the scientific ...
(Date:6/18/2013)... has awarded $12.7 million to match nine academic ... compounds to explore new treatments for patients in ... dystrophy and schizophrenia. The collaborative pilot initiative, called ... led by the National Center for Advancing Translational ... Fund. , The process of developing a new ...
Breaking Biology News(10 mins):Immunity mechanism discovered 2Computer modeling technique goes viral at Brandeis 2NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4
... Oct. 17, 2011 Dr. Randal Halfmann, a research ... 10 investigators selected for the first National Institutes of ... program allows creative early-career scientists to leapfrog the traditional ... investigations. The charter group of awardees will share approximately ...
... It is becoming more and more common to install ... but not all roofs are equally suitable. Scientists from the ... the actual conditions to determine the maximum possible magnitude of ... a particular roof. The scientists have surveyed Gothenburg in a ...
... 17 October 2011 - Genomatix is among the 41 ... European Commission as a high impact project within its ... generation sequencing data analysis and the development of an ... to researchers within and outside the consortium. "To ...
Cached Biology News:UT Southwestern biochemist receives new NIH Early Independence Award 2Now you can determine the solar efficiency of your roof 2
Rad51, N-terminal...
Rabbit polyclonal to WWOX8 ( Abpromise for all tested applications). entrezGeneID: 51741 SwissProtID: Q9NZC7-8...
Goat polyclonal to T7 tag (Agarose) Immunogen: Goats were immunized with MASMTGGQQMG (T7) conjugated to KLH.After multiple immunizations in Freund's adjuvant, serum was collected....
Rabbit polyclonal to Olfactory Receptor LS189744 ( Abpromise for all tested applications)....
Biology Products: